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Abstract
Background:  This study was designed to evaluate the utility of transdermal fentanyl (TDF,
Durogesic®) for the treatment of pain due to osteoarthritis (OA) of the knee or hip, which was
not adequately controlled by non-opioid analgesics or weak opioids. The second part of the trial,
investigating TDF in patients with rheumatoid arthritis (RA) is reported separately.
Methods: Current analgesia was optimised during a 1-week run-in. Patients then received 28 days
treatment with TDF starting at 25 µg/hr, with the option to increase the dose until adequate pain
control was achieved. Metoclopramide was taken during the first week and then as needed.
Results: Of the 159 patients recruited, 75 with OA knee and 44 with OA hip completed the
treatment phase, 30 knee and 18 hip patients entered the one-week taper-off phase. The most
frequently used maximum dose of TDF was 25 µg/hr. The number of patients with adequate pain
control increased during the run-in period from 4% to 27%, and further increased during TDF
treatment to 88% on day 28. From baseline to endpoint, there were significant reductions in pain
(p < 0.001) and improvements in functioning (p < 0.001) and physical (p < 0.001) and mental (p <
0.05) health. Scores for 'pain right now' decreased significantly within 24 hours of starting TDF
treatment. TDF was assessed favourably and 84% of patients would recommend it for OA-related
pain. Nausea and vomiting were the most common adverse events (reported by 32% and 26% of
patients respectively), despite prophylaxis with metoclopramide, which showed limited efficacy in
this setting.
Conclusion: TDF significantly increased pain control, and improved functioning and quality of life.
Metoclopramide appeared to be of limited value in preventing nausea and vomiting; more effective
anti-emetic treatment may enable more people to benefit from strong opioids such as TDF. This
study suggests that four weeks is a reasonable period to test the benefit of adding TDF to improve
pain control in OA patients and that discontinuing therapy in cases of limited benefit creates no
major obstacles.
Background
Osteoarthritis (OA) is a slowly developing articular dis-
ease, characterized mainly by cartilage degeneration,
which is reflected clinically by a gradual development of
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joint pain, stiffness, and loss of full range of movement.
OA is the most common disease to affect synovial joints,
being a major cause of musculoskeletal pain, reduced
quality of life and disability. About 40–60% of patients
with radiological osteoarthritic changes suffer from clini-
cal symptoms of pain, stiffness and loss of mobility [1],
and around 55% of patients with OA report pain as the
worst aspect of the disease [2]. OA is strongly associated
with ageing and, with an increasing elderly population, of
major socioeconomic importance.
Current treatments for OA include a wide range of non-
pharmacological, pharmacological and surgical options,
although evidence to support their effectiveness is varia-
ble and there are no curative treatments. Therapies focus
on reducing symptoms such as pain and stiffness, and
minimalizing functional limitation and disability [3].
However, pain control is the primary aim of treating
patients with OA and, in evaluating symptoms, pain
should be the primary outcome variable [4]. Non-steroi-
dal anti-inflammatory drugs play an important role in the
pharmacological management of OA [5]. However, their
lack of efficacy or potential toxicity may limit their use, in
particular, the withdrawal of certain Cox-2 inhibitors has
restricted the choice of therapies [3,5-7], and problems of
persisting pain remain. Pain from OA may be caused by
factors other than inflammation [8], therefore the logical
next step in the treatment of OA-related pain is the use of
strong opioids. Within a management programme aimed
at improving physical and social function, guidelines rec-
ommend their use when other appropriate therapies have
failed to provide adequate pain relief over a reasonable
period of time [9-13].
Transdermal fentanyl (TDF), providing systemic delivery
of fentanyl at a constant rate for 72 hours [14], has been
shown to be effective in controlling pain and improving
some quality of life parameters for people with chronic
non-malignant pain [15-18]. The efficacy of opioids in
controlling pain in patients with OA has been demon-
strated in three randomized controlled trials [19-21].
Moreover, a prospective study to investigate the efficacy
and tolerability of TDF in 243 patients with severe OA
pain of the knee and/or hip demonstrated significant
reductions in pain at rest and on movement, and provided
evidence of functional improvement [22]. Very few
patients needed doses higher than the 25 µg/hr starting
dose after 30 days of treatment [22].
The present study was undertaken to evaluate the utility
and safety of TDF for the treatment of pain associated with
RA or with OA of the knee or hip, which was not ade-
quately controlled by NSAIDs, Cox-2 inhibitors, paraceta-
mol or weak opioids at optimal doses. As it was an open-
label study, it was not designed to prove efficacy of the
treatment but to investigate practical aspects of opioid
therapy, such as the usefulness of a test-period or concom-
itant use of antiemetic therapy and to serve as a pilot for a
double-blind trial in this patient population. A test period
for evaluation of a patient's response to opioid treatment
is recommended [10] and in this study lasted 4 weeks.
Results from the total study population and from patients
with RA will be reported elsewhere. This paper reports the
effects of TDF on pain and functioning in patients with
OA of the knee or hip.
Methods
Patient selection
All participants were outpatients requiring supplementary
analgesia because of moderate or severe pain, which was
not adequately controlled with paracetamol, NSAIDs,
Cox-2 inhibitors or weak opioids (e.g. tramadol or
codeine). Because non-opioid analgesia is not always
taken at sufficient doses to achieve pain control [24] the
trial employed a run-in period during which analgesia was
optimised. Patients who still had moderate or severe pain
at the end of this period could enter the main treatment
phase of the study. Patients had to be over 50 years old,
have OA of the knee or hip and meet the OA criteria of the
ACR [23]. They had to have radiographic evidence of OA,
and be waiting for hip or knee replacement as indicated
by an orthopaedic surgeon. If participants were taking cor-
ticosteroids and/or NSAIDs they had to have received a
stable dose for at least three months before screening and
expect to remain on a stable dose for the duration of the
trial.
Patients were excluded from the study if they had received
regular treatment with a strong opioid (e.g. morphine) or
had received more than the maximum recommended
dose of weak opioids or other analgesics in the four weeks
before the study. Strong opioids other than fentanyl, sup-
plementary weak opioids or other treatments that might
alter the degree or nature of pain could not be started dur-
ing the study. Patients were excluded if they had continu-
ous pain of non-arthritis origin, or had undergone
surgery/arthroscopy within 3 months, intra/peri articular
injections for arthritis pain (e.g. steroid injection) within
6 weeks, or arthrocentesis within 4 weeks of the study
start.
Study design
Screened patients satisfying the selection criteria each gave
written informed consent before inclusion in this interna-
tional, open, prospective trial. The study was carried out
in accordance with the latest revision of the Declaration of
Helsinki and Good Clinical Practice and was approved by
independent local ethics committees.BMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
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During the one-week run-in period, non-opioid analgesic
treatment was increased to the maximum tolerated or
maximum recommended dose, while weak opioids were
kept stable. All patients with pain control rated as poor or
very poor on a 5-point scale at the end of the run-in period
started treatment for 28 days with transdermal fentanyl
(TDF, Durogesic®) at a dose of 25 µg/h. Patches were
replaced every 72 hours (3 days). Previous non-opioid
analgesia was continued and kept stable, but weak opio-
ids were discontinued. The dose of TDF could be
increased in steps of 25 µg/h every 72 hours (days 3,6 and
9) if required (no maximum dose specified) until ade-
quate pain control was achieved. After 28 days or if neces-
sary for other reasons, e.g. if side effects occurred or the
treatment was not effective, a similar downward titration
regimen was employed. Paracetamol 500 mg tablets were
provided for supplementary analgesia and could be used
in doses of up to 4 g/day. With the exception of paraceta-
mol, other non-opioid analgesics were kept stable and no
short acting opioids were added during down titration.
Metoclopramide 10 mg three times a day was given to all
patients for the prevention of nausea and vomiting during
the first week of treatment, after which it was taken as
needed.
Assessments
Patients were evaluated in the clinic at screening (day -7),
at baseline (day 0), on days 7, 14 (optional because some
clinicians see their patients only every 4 weeks) and on
day 28 (trial end), on other days if dose adjustment was
necessary, and at the end of a one or two week tapering-
off period.
The primary efficacy variable was pain control, evaluated
weekly on a five-point assessment scale ranging from very
poor to excellent. For this assessment, the investigator pre-
sented the question "would you rate your pain control
today as being excellent, good, moderate, poor or very
poor?" Patients also completed a pain assessment ques-
tionnaire (shortened version of the Wisconsin Brief Pain
Inventory (WBPI) [25]) (10-point rating scale: 0, best to
10, worst). The degree of pain after 24 hours of treatment
was assessed by asking patients about the amount of pain
that they had 'right now'. Patients also recorded pain
intensity in a diary on a five-point scale.
Patients completed a treatment assessment questionnaire
consisting of 10 items scored on a Likert scale. The acute
version of the SF-36 quality of life questionnaire [26]
including eight quality of life domains (physical function-
ing, physical role limitations, emotional role limitations,
social functioning, body pain, general mental health,
vitality and general health perceptions) was completed
after the run-in phase and at day 28. Functionality of
patients was assessed at the same time points using the
Western Ontario and McMaster Universities Osteoarthri-
tis Index LK 3.1 (WOMAC questionnaire) [27]. This has
24 questions that are each evaluated on a 5-point severity
scale (0, none to 4, extreme), it assesses three areas: pain
(5 questions), stiffness (2 questions) and functional
impairment (17 questions). Maximum scores for each sec-
tion differ and, therefore, scores are normalized by
weighting severity to assist interpretation.
Statistical analysis
There was no formal sample size calculation. A safety
analysis was performed using data from all patients enter-
ing the trial. An intent-to-treat analysis, comprising all OA
patients with at least one post-baseline measurement of
the primary endpoint (pain control) and treated at least
once with trial medication, was also performed [28].
The ANCOVA model was used to analyse the change from
baseline to endpoint, and the influence of baseline values.
The ANCOVA model was also used to determine differ-
ences by centre. The Wilcoxon signed-rank test was used
to compare intragroup results and results at each time
point or endpoint with baseline, where applicable. Statis-
tical tests were interpreted at the 5% significance level
(two-sided).
Results
Patient characteristics
A total of 159 patients, 102 with OA of the knee and 57 of
the hip, were recruited into the study from 47 centres in
11 countries and started treatment with TDF. Patient char-
acteristics are shown in Table 1. All but three patients used
analgesic treatment in the month before screening and the
treatments were similar for hip and knee groups. The most
commonly used non-opioid analgesics were paracetamol
21%, diclofenac 20% and rofecoxib 10%. The most com-
monly used weak opioid was tramadol (33%). During
this time, half the patients (50%) used a non-opioid only;
28% used a combination of a non-opioid and weak opi-
oid and 18% a weak opioid only.
Table 1: Patient characteristics
OA knee OA hip
N (baseline) 102 57
ITT analysis population 91 52
Mean age (years) ± SE (range) 68 ± 0.9 66 ± 1.2
(49–88) (47–87)
Previous medication (% of patients):
Non-opioids 81 79
Weak opioids 50 40BMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
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Concomitant medication with possible analgesic effects
during the treatment phase included paracetamol (69%),
NSAIDs (45%), weak opioids (33%), Cox-2 inhibitors
(13%), other analgesics (8%), steroids (6%), immu-
nomodulating drugs (1%), and strong opioids (1%). Of
those taking weak opioids, most took them on the first
day of treatment only. Only two patients used opioid res-
cue medication and had to be considered as protocol vio-
lators. There was a reduction in the use of NSAIDs (from
45% to 18%) and Cox-2 inhibitors (9%) and paracetamol
(15%) after the first 24 hours of treatment. Rescue medi-
cation was required by 59% of participants, of whom
almost all used non-opioids, particularly paracetamol.
Most patients suffered from concomitant diseases: 59% of
the patients had currently active cardiovascular diseases,
50% musculo-skeletal, 48% genito-urinary, 47% endo-
crine, and 19% gastrointestinal disease. The most fre-
quently used non-analgesic concomitant therapies during
treatment were metoclopramide 49% and omeprazole
12%.
Discontinuations
Of the 159 participants recruited, 25% withdrew from the
trial during the treatment phase. Reasons for withdrawal
were adverse events (35), insufficent response (1) and
other reasons (4). Around half of the drop-outs (14%, 21
of the 35 due to adverse events) occurred in the first week
of TDF treatment (Figure 1). Of the 48 patients who
started the optional tapering-off phase, 11 (23%) discon-
tinued prematurely (10 because of adverse events and one
was lost to follow-up/surgery). Patients were treated for an
average of 22.3 ± 0.92 days.
Study medication
All patients started at a dose of 25 µg fentanyl/h and daily
doses ranged from 25 to 125 µg/h. The maximum dose
was used by only one patient. The mean daily dose for
week 1 was 26 µg/h, which increased slightly to 37 µg/h
in week 4. Over half (54%) of all patients used 25 µg/h as
a maximum dose during the study (61% OA knee, 42%
OA hip).
Evaluation of efficacy
Primary efficacy variable
Adequate pain control was defined as a score of 'moder-
ate', 'good' or 'excellent' on the 5-point pain control
assessment scale. The proportion of patients with ade-
quate pain control increased during the one-week run-in
period (during which doses of non-opioid analgesia were
optimised) from 4% to 27%. These patients continued in
the study and accounted for the majority of protocol vio-
lators. At baseline, 25% of patients reported very poor
pain control, 48% poor and 25% moderate pain control,
and there was no notable difference between those with
OA knee and OA hip (Table 2). A further increase in the
proportion of patients with adequate pain control was
observed after TDF treatment, particularly in the first week
of treatment (to 74%) when 37% patients reported mod-
erate, 29% good, and 8% excellent pain control. Adequate
pain control was reported by 80% and 88% patients on
days 14 and 28, respectively. At endpoint, 83% of patients
considered their pain controlled, with 37% reporting
moderate, 38% good, and 8% excellent pain control
(Table 2 & Figure 2). About 10% more patients with OA
hip reported good or excellent pain control at endpoint
than those with OA knee. However, of the patients who
already experienced adequate pain control after the run-in
phase (OA knee, 24 moderate and one good pain control;
OA hip, 12 moderate and one good pain control), 50% of
both groups improved further during TDF treatment.
Overall, 81% of participants with OA hip and 75% with
OA knee improved from baseline to endpoint by at least
one pain category.
Effect size
An effect size was calculated by assigning numerical values
to the pain categories (1 = very poor, 2 = poor, 3 = mod-
erate, 4 = good, 5 = very good). This gives a mean pain
control score at baseline of 2.03 (95% CI 1.9, 2.2), rising
to 3.33 (3.2, 3.5) at endpoint and a mean change from
baseline of 1.3 (SD ± 1.14). This gives an absolute effect
size of 1.14.
Secondary efficacy variables
Pain control
Patients reported a significant reduction in pain from
baseline to endpoint for each WBPI item at every time
point (p < 0.001). The mean reduction in 'pain at its
worst' was 1.8 points (from 8.1 to 6.3), 'pain at its least'
was 1.6 points (from 4.4 to 2.8), and 'pain on average' was
2.0 points (from 6.4 to 4.4). The amount of trouble or
bother the pain was causing also decreased by 2.7 points
on average (from 7.2 to 4.5). The mean reduction in 'pain
right now' was 2.6 points (from 6.1 to 3.5) from baseline
to endpoint. A significant reduction in 'pain right now'
was reported as early as 24 hours after baseline (1.3
points, from 6.0 to 4.7).
From patients' diaries, the mean score for degree of pain
was significantly decreased at each time point, and from
severe pain (score 3) to moderate pain (score 2) from the
run-in period to endpoint (p < 0.001). Results were simi-
lar for the patients' highest score for their degree of pain.
Thus, while at baseline 58% (79/137) reported severe/
extreme pain, 4% (5) mild, and only two patients were
without pain, by endpoint 41% (56/138) reported mod-
erate pain, 30% (41) mild and 7% (9) no pain. There was
little difference between the OA knee and OA hip group.BMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
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atient disposition Figure 1
Patient disposition.
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Treatment assessment
In their assessment of treatment (total n = 125, OA knee
82, OA hip 43), 63% of patients rated TDF positively with
respect to pain control and 84% would recommend TDF
for their type of pain. Most patients were satisfied with its
convenience of use (93% thought it easy/extremely easy
to use; 85% were very/somewhat pleased by the way it's
used), and 53% considered side effects were not an issue.
In general, there was a difference of less than 10%
between the OA knee and OA hip groups. In assessing
how they had felt over the past week, the percentage of all
patients who answered good or very good increased dur-
ing the study from 7% (10/142) during the run-in period
to 32% (31/97) in week 4, and their scores at all time
points were significantly better than before treatment (p <
0.001). By the end of the study, help with basic activities
was required by only 28% of patients, with 49% relying
less on their helper.
Quality of life
For the 122 patients who completed the SF-36 quality of
life questionnaire, there were statistically significant
improvements in all domains from baseline to endpoint,
including overall physical health (p < 0.001) and mental
health (p < 0.05) (Table 3). Despite optimization of pre-
vious treatment, quality of life scores were low at baseline,
with the patients' underlying osteoarthritis particularly
Table 2: Pain control assessments (number of patients and 
percentage in each category)
Screening N (%) Baseline N (%) Endpoint N (%)
Very poor 27 (19) 36 (25) 4 (3)
Poor 110 (77) 68 (48) 21 (14)
Moderate 5 (3) 36 (25) 53 (37)
Good 1 (1) 2 (2) 54 (38)
Excellent 0 0 11 (8)
Pain control assessment Figure 2
Pain control assessment.
%
s
u
b
j
e
c
t
s
0
60
60
80
80
100
100
Knee Hip
Screening
Knee Hip
Baseline
Knee Hip
Day 7
Knee Hip
Day 28
Knee Hip
End point
91 N=
Pain relief
52 91 51 88 51 71 35 91 52
40
40
20
20
Excellent
Good
Moderate
Poor
Very PoorBMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
Page 7 of 10
(page number not for citation purposes)
affecting role physical and bodily pain. It was in these two
areas that patients showed greatest absolute improvement
with TDF treatment.
WOMAC
The mean score for all 24 questions from the three sum-
mary parameters (pain, stiffness and physical
functioning) improved significantly from baseline to end-
point for all groups (total population p < 0.001, knee p <
0.001, and hip p < 0.05 for all questions) (Table 4). The
percentage of patients in the combined group and in the
knee sub-group who reported no pain, stiffness or
physical difficulties increased for all items. A similar
increase occurred in the OA hip group except for 'stiffness
after first awakening', 'rising from bed' and 'getting in/out
of the bath' which showed little change.
The majority of participants showed an improvement in
score for the three summary measurements of pain, stiff-
ness and physical functioning, and for the overall
WOMAC score. Mean overall WOMAC score improved
significantly (p < 0.001) from baseline to endpoint (Table
4). In addition, the change from baseline to endpoint in
score for 'pain right now' (from the pain assessment ques-
tionnaire) showed a weak positive correlation with the
change in overall WOMAC score (Spearman correlation
coefficient: non-normalized 0.344 and normalized
0.384).
Evaluation of safety
Adverse events occurring during the treatment phase and
tapering off phase were those associated with strong opi-
oid treatment (Table 5). Adverse events were reported by
6% (9/159) of patients during the run-in period, 65%
(68/104) of patients during the treatment period and 25%
(12/48) during the optional tapering off period. The study
medication was permanently stopped in 25% (39) of
cases, particularly because of nausea (53%), vomiting
Table 3: Quality of life (SF-36 scores)
Domain n Score at baseline (Mean 
± SE)
Mean change between 
baseline and endpoint 
(95% CI)
p-value
Physical functioning
Physical functioning 120 30.0 ± 2.15 4.0 (-0.09, 7.99) <0.05
Role physical 119 11.8 ± 2.38 15.8 (8.89, 22.62) <0.001
Bodily pain 122 23.7 ± 1.54 17.1 (13.21, 20.97) <0.001
General health 119 44.1 ± 2.09 3.6 (0.09, 7.05) <0.05
Mental health
Vitality 119 34.6 ± 1.74 6.3 (3.24, 9.45) <0.001
Social functioning 122 50.3 ± 2.55 7.9 92.99, 12.79( <0.05
Role emotional 117 34.9 ± 3.97 10.8 (1.85, 19.81) <0.05
Mental health 118 53.0 ± 2.06 4.7(1.28, 8.03) <0.05
Summary measures
Physical health 111 27.0 ± 0.69 4.1 (2.73, 5.54) <0.001
Mental health 111 41.7 ± 1.17 2.5 (0.46, 4.64) <0.05
Table 4: WOMAC scores (mean normalised score ± SE, all changes from baseline are statistically significant, p < 0.001 in all cases)
Baseline Endpoint Change from baseline to 
endpoint (95% CI)
Pain 6.3 ± 0.15 4.6 ± 0.21 -1.7 (-2.05, -1.26)
Stiffness 6.1 ± 0.19 4.7 ± 0.23 -1.4 (-1.89, -1.0)
Physical functioning 6.6 ± 0.15 5.1 ± 0.19 -1.5 (-1.83, -1.14)
Overall 19.0 ± 0.4 14.3 ± 0.57 -4.7 (-5.69, -3.62)BMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
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(47%) and dizziness (18%). (No falls or fractures were
reported.) Withdrawal syndrome was reported in two
cases (OA hip) during tapering off – one was mild, the
other moderate, and both resolved without specific treat-
ment. No deaths occurred. Two patients reported at least
one serious adverse event during the treatment phase
(severe asthenia and anorexia in one case, bronchitis in
the other) and one experienced a serious adverse event
during the tapering-off phase (hospitalization due to
chest pain and arrythmia), but these were considered
unrelated to the study drug. There were no clinically sig-
nificant changes in vital signs during the study.
Discussion
The study was intended to evaluate the utility of TDF
under routine conditions and to investigate different prac-
tical issues, such as the usefulness of a test-period and use
of concomitant antiemetic treatment during the first
weeks. It was not designed as a primary efficacy study,
since the efficacy of TDF in providing pain relief has
already been demonstrated [14-18]. For this reason it was
considered unethical to include a placebo control group.
A one-month test period [10] is sufficient to show a role
for TDF in the treatment of pain caused by OA of the knee
or hip that is not adequately controlled by NSAIDs, Cox-
2 inhibitors, paracetamol or weak opioids at optimal
doses. Findings support previous conclusions that OA-
induced pain can be successfully treated with TDF, and
that this may result in improved functioning [22]. Not all
patients with OA of the knee or hip receive adequate doses
of their current non-opioid analgesia because pain control
can be improved in some when doses of these medica-
tions are optimized. Undertreatment of OA-related pain
has been reported previously [24]. Adequate pain control
was achieved for most patients after one week of TDF, at
the starting dose of 25 µg/hr in over half of all patients,
and relief was maintained over the treatment period. Pain
was controlled in 88% of patients after one month with
nearly 40% reporting mild or no pain.
A few patients started treatment with TDF, despite ade-
quate pain control during the run-in phase. These patients
were considered to be protocol violators. However, their
inclusion provided the opportunity to determine whether
TDF could give additional benefits to these patients above
those already gained by their current medications. About
half of these patients achieved further pain reduction
while treated with TDF.
Over the treatment period, the numbers of all patients
using other analgesics, especially NSAIDs decreased sub-
stantially (from 45% to 19%). This may be beneficial in
reducing side effects such as gastrointestinal bleeding.
Nearly all patients taking weak opioids took them on the
first day of treatment only when serum levels of fentanyl
had not yet achieved steady state. Paracetamol may be
useful for breakthrough pain in some patients but need
for rescue medication should be evaluated on an
individual basis. Metoclopramide did not appear to pre-
vent nausea or vomiting.
Treatment was considered favourable in terms of efficacy,
side effects and convenience. A preference for treatment
with TDF over sustained release morphine has previously
been shown by patients with chronic non-cancer pain
[16].
The general health measure, SF-36, indicated that control
of pain significantly improved both physical and mental
components of quality of life. The improvement in men-
tal health may be related to improved functioning which
permits greater social activity. In spite of similar pain con-
trol, patients with OA of the hip appeared to have slightly
more difficulty with stiffness and general mobility than
those with OA of the knee, such as getting in/out of the
bath or bed, probably due to the location and function of
these joints.
WOMAC is a reliable, valid and responsive multidimen-
sional, self-administrated outcome measure designed spe-
cifically to evaluate patients with OA of the knee or hip
[27]. Overall pain, stiffness and function significantly
improved after one month of TDF treatment for both OA
knee and OA hip patients, with improvements in nearly
all items of WOMAC summary categories. Quality of life
would be expected to be improved with pain relief,
although significant pain relief would not necessarily be
associated with reduced stiffness and increased physical
function [29]. Increased functioning was also indicated by
the fact that half of all patients required less help with
Table 5: Adverse events (AEs) reported during the treatment 
phase and tapering off phase by >5% of participants
Preferred term Total AEs n (%)
Treatment phase (N = 104)
Nausea 51 (32%)
Vomiting 41 (26%)
Somnolence 25 (16%)
Dizziness 14 (9%)
Constipation 10 (6%)
Asthenia 9 (6%)
Pruritus 8 (5%)
Tapering off phase (N = 42)
Nausea 5 (10%)
Vomiting 3 (6%)BMC Musculoskeletal Disorders 2005, 6:31 http://www.biomedcentral.com/1471-2474/6/31
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daily activities of living. Return of a full range of motion
is unlikely to occur when marked structural damage of the
joint has occurred.
Overall, the spectrum of reported side effects was consist-
ent with those commonly associated with opioid therapy
and with previous experience with TDF. Constipation was
not a problem for this patient population as with other
patients receiving TDF for non-cancer pain or cancer pain
[16,29,30], and tolerance to other side effects is likely to
develop with continued treatment [31]. In addition to
nausea and vomiting, patients should be warned of the
possibility of dizziness when starting strong opioid treat-
ment. This is especially important for the elderly OA
population in order to prevent falls. In the present study,
9% of patients reported dizziness.
As might be expected in an elderly population, many
patients had co-existing diseases. For example, 59% had
cardiovascular disease on entry, which is of particular
interest given the concern about the cardiovascular safety
of some Cox-2 inhibitors which, since this trial was under-
taken, has led to the withdrawal of rofecoxib.
This trial demonstrates that patients with OA of the knee
or hip continue to experience pain even at optimal doses
of their non-opioid treatment, providing a major reason
why patients and clinicians alike are often dissatisfied
with current therapies. The study also shows that patients
with OA benefit from additional pain control provided by
TDF [32]. Clinicians are beginning to accept that strong
opioids are well tolerated and effective and should be
made available when non-opioids have failed to control
pain [33]. Our findings support this reasoning and sug-
gest that opioids should be made more widely available
where appropriate.
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